Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
15
UTMD Quote, Financials, Valuation and Earnings
Last price:
$55.95
Seasonality move
:
2.81%
Day range:
$55.00 - $56.37
52-week range:
$51.26 - $65.56
Dividend yield:
2.18%
P/E ratio:
15.84x
P/S ratio:
4.76x
P/B ratio:
1.52x
Volume:
18.9K
Avg. volume:
11.5K
1-year change:
-12.88%
Market cap:
$179.4M
Revenue:
$40.9M
EPS (TTM):
$3.53
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
-- | -- | -- | -- | -- |
|
AGEN
Agenus, Inc.
|
$80.4M | $2.20 | 144.6% | -70.59% | $12.33 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$1.4M | -$0.42 | 19.84% | -177.23% | $9.00 |
|
CRIS
Curis, Inc.
|
$2.9M | -$0.60 | -1% | -72.35% | $16.33 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$55.99 | -- | $179.4M | 15.84x | $0.31 | 2.18% | 4.76x |
|
AGEN
Agenus, Inc.
|
$4.06 | $12.33 | $138.1M | -- | $0.00 | 0% | 1.03x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$5.94 | $9.00 | $215.8M | -- | $0.00 | 0% | 49.27x |
|
CRIS
Curis, Inc.
|
$1.35 | $16.33 | $17.5M | -- | $0.00 | 0% | 1.29x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.75 | $11.00 | $140.7M | 25.18x | $0.00 | 0% | 2.23x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
0.2% | 1.065 | 0.12% | 29.22x |
|
AGEN
Agenus, Inc.
|
510.35% | 4.383 | 285.06% | 0.03x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
ARMP
Armata Pharmaceuticals, Inc.
|
216.44% | 3.715 | 164.57% | 0.11x |
|
CRIS
Curis, Inc.
|
192.35% | 3.282 | 144.76% | 0.62x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
UTMD
Utah Medical Products, Inc.
|
$5.1M | $2.6M | 9.75% | 9.78% | 26.61% | $3.9M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
ARMP
Armata Pharmaceuticals, Inc.
|
$789K | -$7.8M | -57.86% | -- | -670.92% | -$4.5M |
|
CRIS
Curis, Inc.
|
$3.1M | -$6.9M | -147.67% | -461.34% | -218.01% | -$5.6M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
Utah Medical Products, Inc. vs. Competitors
-
Which has Higher Returns UTMD or AGEN?
Agenus, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -116.82%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About UTMD or AGEN?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 203.78%. Given that Agenus, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Agenus, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 AGENAgenus, Inc.2 1 0 -
Is UTMD or AGEN More Risky?
Utah Medical Products, Inc. has a beta of 0.327, which suggesting that the stock is 67.29% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.510, suggesting its more volatile than the S&P 500 by 51.01%.
-
Which is a Better Dividend Stock UTMD or AGEN?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.18%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or AGEN?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Utah Medical Products, Inc.'s net income of $2.6M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.84x while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 1.03x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.84x $9.8M $2.6M AGENAgenus, Inc.1.03x -- $30.2M $63.9M
-
Which has Higher Returns UTMD or AIM?
AIM ImmunoTech has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -10571.43%. Utah Medical Products, Inc.'s return on equity of 9.78% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About UTMD or AIM?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Utah Medical Products, Inc., analysts believe AIM ImmunoTech is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 AIMAIM ImmunoTech1 0 0 -
Is UTMD or AIM More Risky?
Utah Medical Products, Inc. has a beta of 0.327, which suggesting that the stock is 67.29% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock UTMD or AIM?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.18%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or AIM?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Utah Medical Products, Inc.'s net income of $2.6M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.84x while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.84x $9.8M $2.6M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns UTMD or ARMP?
Armata Pharmaceuticals, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -2301.55%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Armata Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M ARMPArmata Pharmaceuticals, Inc.68.08% -$0.74 $82.1M -
What do Analysts Say About UTMD or ARMP?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 51.52%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 ARMPArmata Pharmaceuticals, Inc.1 0 0 -
Is UTMD or ARMP More Risky?
Utah Medical Products, Inc. has a beta of 0.327, which suggesting that the stock is 67.29% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.
-
Which is a Better Dividend Stock UTMD or ARMP?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.18%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or ARMP?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.84x while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 49.27x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.84x $9.8M $2.6M ARMPArmata Pharmaceuticals, Inc.49.27x -- $1.2M -$26.7M
-
Which has Higher Returns UTMD or CRIS?
Curis, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of -243.36%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Curis, Inc.'s return on equity of -461.34%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M CRISCuris, Inc.98.52% -$0.49 $15.9M -
What do Analysts Say About UTMD or CRIS?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Curis, Inc. has an analysts' consensus of $16.33 which suggests that it could grow by 1109.88%. Given that Curis, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Curis, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 CRISCuris, Inc.3 0 0 -
Is UTMD or CRIS More Risky?
Utah Medical Products, Inc. has a beta of 0.327, which suggesting that the stock is 67.29% less volatile than S&P 500. In comparison Curis, Inc. has a beta of 4.025, suggesting its more volatile than the S&P 500 by 302.512%.
-
Which is a Better Dividend Stock UTMD or CRIS?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.18%. Curis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Curis, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or CRIS?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are larger than Curis, Inc. quarterly revenues of $3.2M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Curis, Inc.'s net income of -$7.7M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.84x while Curis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 1.29x for Curis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.84x $9.8M $2.6M CRISCuris, Inc.1.29x -- $3.2M -$7.7M
-
Which has Higher Returns UTMD or PLX?
Protalix Biotherapeutics, Inc. has a net margin of 26.81% compared to Utah Medical Products, Inc.'s net margin of 13.19%. Utah Medical Products, Inc.'s return on equity of 9.78% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital UTMDUtah Medical Products, Inc.51.56% $0.82 $118.5M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About UTMD or PLX?
Utah Medical Products, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 528.57%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Utah Medical Products, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Utah Medical Products, Inc..
Company Buy Ratings Hold Ratings Sell Ratings UTMDUtah Medical Products, Inc.0 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is UTMD or PLX More Risky?
Utah Medical Products, Inc. has a beta of 0.327, which suggesting that the stock is 67.29% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock UTMD or PLX?
Utah Medical Products, Inc. has a quarterly dividend of $0.31 per share corresponding to a yield of 2.18%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Utah Medical Products, Inc. pays 30.43% of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend. Utah Medical Products, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios UTMD or PLX?
Utah Medical Products, Inc. quarterly revenues are $9.8M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Utah Medical Products, Inc.'s net income of $2.6M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Utah Medical Products, Inc.'s price-to-earnings ratio is 15.84x while Protalix Biotherapeutics, Inc.'s PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Utah Medical Products, Inc. is 4.76x versus 2.23x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income UTMDUtah Medical Products, Inc.4.76x 15.84x $9.8M $2.6M PLXProtalix Biotherapeutics, Inc.2.23x 25.18x $17.9M $2.4M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 171.49% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is up 0.01% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 4.15% over the past day.
